Gastrointestinal System
Gastrointestinal System
Focused on unmet clinical needs in gastrointestinal treatments, we are building advanced platforms such as controlled-release, hot-melt extrusion, and osmotic pumps to provide patients with safe, effective, and affordable medicines.
Innovation Drug Pipeline
Projects
Target
Indications
PCC
IND
Phase I/II
Phase III
NDA
Launched
Projects：
Aurantii Fructus Immaturus Total Flavonoids Tablet
Target：
-
Indications：
Gastrointestinal motility
Projects
Target
Indications
PCC
IND
Phase I/II
Phase III
NDA
Launched
Aurantii Fructus Immaturus Total Flavonoids Tablet (Brand name: Orante) is an innovative Class 1.2 traditional Chinese medicine developed by Qingfeng Pharmaceutical. The main ingredient is total flavonoid extract of Aurantii Fructus Immaturus, used for functional dyspepsia.
The two Phase III clinical trials (placebo-controlled and compared with Domperidone) show that Aurantii Fructus Immaturus Total Flavonoids Tablet have good therapeutic effects on common symptoms of functional dyspepsia (such as liver-stomach disharmony, spleen-stomach damp-heat, food stagnation, and spleen-stomach deficiency). The trials also showed that symptom relief persisted after discontinuation, with a better safety profile and sustained efficacy than the active comparator drug.
Marketed Products
Xinyang® Abiraterone Acetate Tablets
Xinyang® Abiraterone Acetate Tablets are a highly selective CYP17 enzyme inhibitor that targets multiple sites of androgen biosynthesis throughout the body.
Ligesitai® Sorafenib Tosylate Tablets
Ligesitai® Sorafenib Tosylate Tablets are a multi-target oral medication for treating tumors, with dual mechanisms of action. It inhibits tumor angiogenesis by blocking VEGFR and PDGFR and suppresses tumor cell proliferation by blocking the Raf/MEK/ERK signaling pathway, indirectly inhibiting tumor cell growth. It was approved for market in August 2020. It is primarily used for the treatment of renal cancer, liver cancer, and thyroid cancer.
Xinzhuo® Afatinib Dimaleate Tablets
Xinzhuo® Afatinib Dimaleate Tablets are the first irreversible ErbB family receptor blockers. They covalently bind to the kinase regions of EGFR (ErbB1), HER2 (ErbB2), and HER4 (ErbB4), irreversibly inhibiting tyrosine kinase autophosphorylation, leading to downregulation of ErbB signaling and inhibiting tumor cell proliferation. Xinchuo® was approved for market in August 2021 and is indicated for: Locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR gene-sensitive mutations in patients who have not previously received EGFR tyrosine kinase inhibitors (TKI) treatment. Locally advanced or metastatic squamous cell carcinoma of non-small cell lung cancer (NSCLC) with disease progression during or after platinum-based chemotherapy.
